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http://dx.doi.org/10.1016/j.ccr.2014.03.008SUMMARYChromosomal translocations disrupting MLL generate MLL-fusion proteins that induce aggressive
leukemias. Unexpectedly, MLL-fusion proteins are rarely observed at high levels, suggesting excessive
MLL-fusions may be incompatible with a malignant phenotype. Here, we used clinical proteasome inhibitors,
bortezomib and carfilzomib, to reduce the turnover of endogenous MLL-fusions and discovered that
accumulated MLL-fusions induce latent, context-dependent tumor suppression programs. Specifically, in
MLL pro-B lymphoid, but not myeloid, leukemias, proteasome inhibition triggers apoptosis and cell cycle
arrest involving activation cleavage of BID by caspase-8 and upregulation of p27, respectively. Furthermore,
proteasome inhibition conferred preliminary benefit to patients withMLL-AF4 leukemia. Hence, feasible stra-
tegies to treat cancer-type and oncogene-specific cancers can be improvised through harnessing inherent
tumor suppression properties of individual oncogenic fusions.INTRODUCTION
During tumorigenesis, the accumulation of genetic and epige-
netic alterations is a key mechanism that contributes to the
malignant phenotype and is a hallmark of cancer (Hanahan
and Weinberg, 2011). Driver mutations appear important for
tumorigenesis, and tumor cells frequently develop dependence
on select oncogenes during cancer evolution for tumor mainte-
nance and malignant progression, hence, develop ‘‘oncogeneSignificance
The oncogene addiction hypothesis posits that cancers driven
of the culprit oncoprotein. Surprisingly, recent studies have dem
pression activity that requires downregulation for tumorigenesi
tumor suppression activity and if so, whether it could be redire
leukemia cells were sensitive to bortezomib and carfilzomib.W
therapies with bortezomib and observed complete remission
both had pro-B leukemia. Our study supports further exploratio
genes for cancer treatment.
530 Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc.addiction’’ (Sharma and Settleman, 2007). In several exemplary
cases, oncogene addiction can be broken by molecularly
targeted agents aimed at therapeutic inhibition of the onco-
genic signaling pathway or the oncoprotein itself (Luo et al.,
2009).
Classically known oncogenes, such as MYC, RAS, and E2F1,
induce transformation and promote tumorigenesis in various
settings, but paradoxically incur cellular tumor suppression
responses, such as cellular senescence and programmed cellby select oncogenes are vulnerable to therapeutic inhibition
onstrated that oncogenes have cryptic intrinsic tumor sup-
s. Here, we investigatedwhetherMLL-fusions possess latent
cted to inflict self-destruction. Indeed, we found pro-B MLL
e treated five patients withMLL leukemia that failed standard
in one patient and hematological improvement in another;
n of latent tumor suppression properties of individual onco-
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magenesis depends on an inhibition of apoptosis, often through
upregulation of prosurvival proteins of the anti-apoptotic BCL-
2 family. Like many oncogenes, MYC is not directly druggable,
thereby posing challenges to cancer therapy development.
Intriguingly, tumorigenesis by oncogenes may involve cell-
type specificity and proper oncogene dosage (Lowe et al.,
2004). Regarding oncogene dosage, for example, whereas
moderate MYC expression leads to transformation, excess
MYC accumulation triggers apoptosis. Thus, tumor suppres-
sive surveillance may depend on a threshold of oncogene
abundance.
The mixed-lineage leukemia gene (MLL) encodes a large,
500 kDa nuclear protein that contains multiple conserved do-
mains, including a SET domain endowed with methlytransferase
activity that is used to methylate histone H3 at lysine 4 (H3K4), a
mark associated with euchromatin and active transcription (Dou
et al., 2006; Milne et al., 2002). MLL functions as heterodimeric
complexes composed of its amino (MLLN320) and carboxy
(MLLC180) terminal segments following site-specific proteolysis
of its full-length precursor polypeptide by the Taspase1 protease
(Hsieh et al., 2003; Oyama et al., 2013; Takeda et al., 2006, 2013).
Additional regulation of MLL function involves its biphasic accu-
mulation and proteasome-mediated degradation coinciding with
the cell cycle, coordinated by the ubiquitin-proteasome system
E3 SCFSkp2 and APCCdc20 at S and M phases, respectively
(Liu et al., 2007, 2010). Interestingly, MLL is also subject to pro-
teasome-mediated degradation by the ECSASB2 E3 ligase (Wang
et al., 2012).
Chromosome 11q23 translocations involvingMLL account for
80% of infant leukemias, 10% of adult acute leukemias, and
33% of therapy-related myelodysplastic syndrome/secondary
acute leukemias (Liu et al., 2009). LeukemogenicMLL transloca-
tions fuse the common MLL 50 part that encodes its N-terminal
1,400 amino acid in framewithmore than 60 translocation part-
ner genes (TPGs) (Krivtsov and Armstrong, 2007; Liedtke and
Cleary, 2009; Liu et al., 2009; Muntean and Hess, 2012; Yip
and So, 2013). MLL translocations involving fusion of chromo-
some 11 with chromosomes 4 and 19 resulting in MLL-AF4
andMLL-ENL, respectively, are prevalent in acute lymphoblastic
leukemia (Bhojwani et al., 2009), whereas its translocations with
chromosomes 9 and 6 producing MLL-AF9 and MLL-AF6,
respectively, are commonly associated with acute myeloid leu-
kemia (AML). MLL-induced leukemias often show resistance to
chemotherapies and consequently, patients with these malig-
nancies typically undergo rapid relapse following these conven-
tional treatments. The lack of adequate therapy for leukemias
is likely due, in part, to the wide diversity of TPGs and potent
oncogenic capacity of MLL-TPG fusion proteins. Hence, much
remains to be learned about the activities of the MLL-fusion
proteins.
Unexpectedly, expression of certain MLL-fusion products
appears to compromise leukemia cell survival (Ayton and
Cleary, 2001; Caslini et al., 2000; Xia et al., 2005), and clinical
samples from leukemia patients rarely show high-level accu-
mulation of these oncoproteins. Here, we investigated the hy-
pothesis that the accumulation of high levels of endogenous
MLL-fusion proteins is detrimental to leukemia cell survival
and proliferation.RESULTS
MLL-Fusion Proteins Accumulate upon Proteasome
Inhibition
We previously observed that MLL-fusion proteins typically do
not reach excessive levels in vivo (Liu et al., 2007, 2010), indi-
cating that their high-levels may result in undesirable cellular
consequences. To examine this further, we monitored the
accumulation of MLL and MLL-fusion proteins upon protea-
some inhibition in different human leukemia cell lines, including
pro-B MLL leukemia cell lines RS4;11 and SEM, and pro-B
non-MLL; that is, without MLL translocation, leukemia lines
JM1 and REH (Drexler et al., 2004; Figure 1A). Before exposure
to bortezomib, RS4;11 and SEM cell lines had detectable
MLL-AF4 levels that were more abundant than in MLL, which
is consistent with the fact that MLL-fusion proteins exhibit
reduced turnover by the cell-cycle-dependent ubiquitin pro-
teasome system (Liu et al., 2007) and that MLL-fusions can
reduce the levels of MLL (Liu et al., 2010). Significantly, upon
exposure to bortezomib, the levels of MLL and MLL-fusion
proteins increased in all tested leukemia cell lines (Figure 1B).
In pro-B MLL leukemia cells, MLL-AF4 levels increased over
the duration of bortezomib treatment, and a similar increase
of MLL-AF9 was observed in treated myelogenous MLL cell
lines THP-1 and NOMO-1 (Figure 1B). Furthermore, stability
analysis demonstrated that MLL-AF4 has a longer protein
half-life than MLL (Figure S1A available online). Therefore,
MLL-fusion proteins in leukemia cells are continually turned
over and their levels appear restricted from reaching an
overabundance.
Pro-B MLL Leukemia Cells Show Greater Sensitivity
upon Proteasome Inhibition, Exhibiting Apoptosis and
G2/M Cell Cycle Block
Next, we investigated what effect bortezomib treatment has on
MLL leukemia cells. Importantly, the pro-B MLL leukemia cell
lines RS4;11 and SEM showed a dosage-dependent reduction
in cell viability (Figure 1C). The reduction in cell viability observed
in these lines was greater than that in non-MLL pro-B lines JM1
and REH cells (Figure 1C). The half-maximal inhibitory concen-
tration of bortezomib was determined to be approximately
3 nM in both RS4;11 and SEM cell lines, which was ten times
lower than that for the other cell lines tested (Figure 1C). This dif-
ference in sensitivity to proteasome inhibition was confirmed
with carfilzomib, another US Food and Drug Administration-
approved proteasome inhibitor (Demo et al., 2007; Figure S1B).
Interestingly, in AML, MLL leukemia lines MV4-11, MOLM-13,
NOMO-1, and THP-1 were similarly resistant to bortezomib as
non-MLL lines HL60 and U937 (Figure 1C). Notably, despite dis-
playing significant sensitivity to bortezomib, RS4;11 and SEM
cells displayed equivalent sensitivity as the other leukemia lines
to common chemotherapeutic agents, including doxorubicin
(DNA topoisomerase II inhibitor), etoposide (DNA topoisomerase
II inhibitor), paclitaxel (microtubule stabilizing agent), cisplatin
(DNA cross-linker), and dexamethasone (corticosteroid) (Figures
S1C–S1G). Thus, these pro-B MLL-AF4 leukemia cells do not
have an intrinsic cell survival impairment. We concluded that
pro-B MLL-AF4 leukemia cells display a selective sensitivity to
proteasome inhibition.Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc. 531
Figure 1. Pro-B MLL-AF4 Leukemia Cells
Display Marked Sensitivity to Proteasome
Inhibitors
(A) Immunoblots of MLL (MLLN320) and the MLL-
AF4 fusion protein in pro-B leukemia cell lines.
Antibody against the shared amino terminus of
MLL among all MLL-fusions was utilized. The
b-actin blot is included to demonstrate similar
loading.
(B) Immunoblots of MLLN320 and MLL-fusion pro-
teins in the indicated cell lines at 0, 3, 6, and 9 hr
after treatment with 5 nM bortezomib.
(C) Cell viability was measured with MTT assay
24 hr after the addition of bortezomib at the indi-
cated concentrations. Top, viability plots of pro-B
ALL cell lines; bottom, of AML cell lines. Relative
cell viability was calculated by the absorbance
reading for bortezomib-treated cells normalized by
untreated cells. Error bars reflect ± SEMmeasured
from three independent experiments.
See also Figure S1.
Cancer Cell
Oncogenic MLL-Fusion-Dependent Tumor SuicideWe sought to better understand the susceptibility to bortezo-
mib in the pro-B MLL-AF4 leukemia cells. Annexin V staining of
RS4;11, SEM, JM1, and REH cells following exposure to borte-
zomib confirmed that the pro-B MLL-AF4 leukemia cells were
more prone to undergo cell death than their pro-B non-MLL leu-
kemia counterparts (Figure 2A). Furthermore, cell cycle analysis
demonstrated that compared to JM1 and REH, the RS4;11 and
SEM cell lines displayed a reduction in the S phase and an accu-
mulation in the G2/M phase (Figure 2B). These cells also dis-
played a greater ratio of sub-G1 ploidy (Figure 2B), indicative
of increased DNA cleavage that associates with apoptosis.
These results suggest that bortezomib selectively induces
apoptosis and G2/M block in pro-B leukemia cells bearing the
MLL-AF4 oncoprotein.
To investigate that MLL-AF4 could be involved in the borte-
zomib-induced cytotoxicity, we performed shRNA-mediated
knockdown studies. SEM and RS4;11 cells were retrovirally
transduced with an shRNA specifically targeting the junction
sequence of MLL-AF4 (shMLL-AF4) or a control shRNA.
Whereas the control shRNA had no effect on bortezomib-
induced killing, shMLL-AF4 led to a reduction in bortezomib-trig-
gered apoptosis (Figures 2C, S2A, and S2B). Furthermore,
ectopic expression of MLL-AF4 in SEM cells appeared to render
increased sensitivity to bortezomib (Figure S2C). Conversely,
because non-MLL pro-B leukemia cells were less susceptible
to the bortezomib-stimulated cytotoxicity (Figure 1), we deter-
mined if ectopic expression of MLL-fusions in REH cells would
alter their sensitivity to proteasome inhibition. To this end, we
generated REH cell lines stably transduced with MLL-AF4,
MLL-AF9, or MLL-ENL (Figure 2D). Remarkably, introduction of
MLL-AF4, MLL-AF9, or MLL-ENL caused REH cells to become
more susceptible to bortezomib (Figure 2D). Of note, reconsti-
tution of the common MLL amino-terminus alone in REH cells532 Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc.(Figures 2D and S2D) or MLL-AF4 or
MLL-ENL in HL60 myelogenous leukemia
cells (Figure S2E) did not confer bortezo-
mib sensitivity. Altogether, these resultsdemonstrate that apoptosis induced by proteasome inhibition
in the pro-B MLL leukemia cells is likely dependent on the
MLL-fusion proteins. They also suggest that distinct leukemia
cells are intrinsically equipped with an oncogenic fusion protein
that could be retooled as a self-destructive weapon.
Bortezomib Triggers Apoptosis in Pro-B MLL Leukemia
through BID Activation
Multiple death stimuli culminate in activation of the pro-apoptotic
BCL-2 cascade, resulting in mitochondrial outer membrane per-
meabilization and cytochrome c efflux into the cytosol for cas-
pase activation (Danial and Korsmeyer, 2004; Kim et al., 2006,
2009; Ren et al., 2010). To determinewhether caspase-mediated
apoptosis is involved in bortezomib-induced cancer cell death,
RS4;11 and SEMcells were cotreatedwith zVAD, a pan-caspase
inhibitor, during their exposure to bortezomib. Cotreatment of
zVAD efficiently reduced the number of annexin V-positive cells
caused by bortezomib (Figures 3A and S3A). We next examined
if anti-apoptotic BCL-2 family proteins BCL-2 or BCL-XL could
suppress this death. In RS4;11 and SEM cells, retroviral trans-
duction of BCL-2 or BCL-XL disrupted bortezomib-induced cell
death (Figures 3B and S3B), indicating that proteasome inhibi-
tion induces cell death through the mitochondrion-dependent
apoptotic pathway. Consistent with these pharmacological and
genetic evidences of apoptosis, RS4;11 and SEM, but not JM1
or REH, cells displayed cleavage of caspase-3 and poly ADP-
ribose polymerase (Figure 3C). Thus, in pro-B MLL leukemia
cell lines, bortezomib induces mitochondrial apoptosis that can
be blocked by anti-apoptotic BCL-2 and BCL-XL.
Bortezomib has been reported to trigger apoptosis in multiple
myeloma cells through both (nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB)-dependent and -indepen-
dent mechanisms (Adams, 2004; Cvek and Dvorak, 2011;
Figure 2. Proteasome Inhibition Induces Apoptosis and Cell Cycle Arrest in the Pro-B Leukemia Cells Harboring MLL-Fusion Proteins
(A) Cells were stained with annexin V after treatment with 5 nM bortezomib.
(B) Cell cycle profiles were analyzed upon a 12 hr exposure to 5 nM bortezomib. Cell cycle profiling was performed after a 30 min pulse incorporation of
bromodeoxyuridine (BrdU), followed by flow cytometry analyses. Regions of the fluorescence-activated cell sorting plot delineating different cell cycle phases are
specified.
(C) Top, immunoblots demonstrated shMLL-AF4-mediated specific knockdown ofMLL-AF4 but not MLL (MLLN320) in SEM cells. The indicated cells were treated
with 12 hr of 5 nM bortezomib. Bottom, MTT assays of the indicated cells after a 24 hr exposure to 5 nM bortezomib are presented.
(D) Left, immunoblots demonstrated exogenous expression of FLAG-tagged MLL-AF4, MLL-AF9, MLL-ENL, and MLL (amino acids 1–1,400), determined by an
anti-MLL amino-terminus antibody. Right, MTT assay were performed after a 24 hr treatment with 5 nM bortezomib.
Error bars reflect ± SEM calculated from three independent experiments. *Indicates statistical significance (p < 0.05). See also Figure S2.
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Figure 3. The Cell Death of Pro-B Leukemia
Cells Induced upon Proteasome Inhibition
Involves the Extrinsic Apoptotic Pathway
(A) The percentage of annexin V-positive cells was
determined after a 12 hr exposure to 5 nM borte-
zomib with or without cotreatment of 50 mM zVAD.
(B) Annexin V staining of the indicated cells
was assessed after a 12 hr treatment with 5 nM
bortezomib.
(C) Immunoblots of key apoptosis regulators of
the indicated pro-B leukemia cells before and after
a 12 hr exposure to 5 nM bortezomib.
(D) Annexin V staining of the indicated cells
was assessed after a 12 hr treatment with 5 nM
bortezomib.
Error bars reflect ± SEM calculated from three
independent experiments. See also Figure S3.
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RS4;11 and SEM cells, no increase was seen in the levels of I-kB,
a major regulatory protein of NF-kB complexes that is controlled
by stimulus-dependent proteasome-mediated degradation (Fig-
ure 3C). This suggests that NF-kB inhibition is unlikely to be the
main mechanism underlying bortezomib-induced apoptosis.
The observation that bortezomib-induced apoptosis can be
inhibited by BCL-2 and BCL-XL indicates the involvement of
mitochondrion-dependent cell program. In response to death
signals, activator BH3-only molecules, including truncated BID
(tBID), BIM, and PUMA, directly interact with BAX and BAK to
induce a stepwise structural reorganization and the ensuing
oligomerization of BAX and BAK, leading to mitochondrial outer
membrane permeabilization (Cheng et al., 2001; Kim et al., 2006,
2009; Ren et al., 2010). To interrogate further, we examined the
levels of pro- and anti-apoptotic BCL-2 family proteins—key
players that integrate death and survival signals at themitochon-
dria (Cvek and Dvorak, 2011; Fennell et al., 2008). In RS4;11 and
SEM cells, but not JM1 or REH cells, conversion of BID to tBID
p15 was observed upon proteasome inhibition (Figure 3C), sug-
gesting that caspase-8 is likely activated to cleave BID. BID nor-
mally resides in the cytosol, and, once cleaved by caspase-8
(tBID), translocates to the mitochondrion where it activates
BAX and BAK to induce cytochrome c release, serving as
an amplification loop for caspase-3 activation. Caspase-8 can
be autoactivated within the death-inducing signaling complex
upon ligation of death receptors such as FAS. Indeed, quantita-
tive RT-PCR (qRT-PCR) analysis of RS4;11 and SEM cells
showed that bortezomib increased transcript levels of FAS,
FASLG, and CASP8, likely contributing to the activation of cas-
pase-8, but not those of HOXA9 orMEIS1, two key downstream534 Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc.leukemogenic effectors of MLL-AF4
(Figures S3C–S3H). Furthermore, borte-
zomib-mediated transcriptional upregu-
lation of CASP8, FAS, and FASLG was
inhibited by knockdown of MLL-AF4
in SEM cells (Figures S3I–S3K). Protea-
some inhibition was reported to increase
the duration and amount of caspase-8
activity upon death receptor engagement
(Gonzalvez et al., 2012). To further interro-gate the involvement of caspase-8 activation in bortezomib-
induced apoptosis in pro-B MLL leukemia, we exogenously
expressed CrmA, an inhibitor of caspase-8 (Garcia-Calvo
et al., 1998; Muzio et al., 1996), and found that CrmA expression
significantly protected SEM cells from bortezomib-induced
apoptosis (Figure 3D). As previously reported, MCL-1 protein,
which is rapidly turned over by the ubiquitin-proteasome system,
was stabilized by bortezomib (Figure 3C; Perciavalle and Opfer-
man, 2013). However, the potent inactivator of MCL-1, NOXA,
was also highly induced by bortezomib (Figure 3C). Conse-
quently, NOXA would prevent MCL-1 from sequestering tBID,
allowing tBID to activate BAX and BAK (Kim et al., 2006).
Although both NOXA and PUMA are known transcriptional
targets of p53, only NOXA was induced upon proteasome inhibi-
tion. Furthermore, the levels of p53 did not correlate with borte-
zomib-induced apoptosis in these cell lines that carry wild-type
p53 alleles based on the cancer cell line encyclopedia (Barretina
et al., 2012; Figure 3C). Hence, p53 is unlikely to play a role in
proteasome inhibitor-induced apoptosis in our experimental
setting. Taken together, these results are consistent with a
model in which proteasome inhibition activates caspase-8
to convert BID to tBID, which in turn, initiates BAX- and BAK-
dependentmitochondrial apoptosis in pro-BMLL leukemia cells.
Bortezomib Induces Cell Cycle Dysfunction in RS4;11
and SEM Cells through p27 Activation
Because bortezomib triggers both apoptosis and cell cycle
arrest (Figures 2A and 2B), we examined whether these two pro-
cesses are separable. First, we determined if the bortezomib-
induced G2/M block is affected when apoptosis is abrogated.
For this, anti-apoptotic BCL-XL was ectopically expressed in
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resistance to apoptosis, the BCL-XL-expressing SEM cells still
exhibited a G2/M block upon proteasome inhibition (Figure 4A).
Similarly, cotreatment of zVAD in SEMcells did not affect the G2/
M block caused by bortezomib (Figure S4A). To investigate
further, we performed immunoblotting to detect levels of cyclins
and cyclin-dependent kinase inhibitors, key regulators of cell
cycle progression. In RS4;11 and SEM cells, we observed a
marked upregulation of p27 that correlated with the bortezo-
mib-induced cell cycle arrest (Figure 4B). In contrast, the levels
of p15, p16, p21, and cyclins D1, E2, A, B1, were unchanged
by bortezomib, and hence these were unlikely to be directly
involved in the bortezomib-induced cell cycle arrest (Figure 4B).
We next examined the role of p27 in the bortezomib-induced
G2/M block. In SEM-BCL-2 cells, knockdown of p27 led to an
attenuation of the bortezomib-induced G2/M block (Figure 4C),
indicating that p27 is important for these pro-B MLL leukemia
cells to undergo cell cycle arrest in response to proteasome in-
hibition. Levels of p27 can be controlled by protein degradation
(Chu et al., 2008) and by direct transcriptional activation through
MLL and MLL-AF4 (Milne et al., 2005; Xia et al., 2005). Thus, we
examined if the upregulation of p27 upon bortezomib treatment
depends on MLL-AF4. qRT-PCR analysis showed that the p27
mRNA level in SEM and RS4;11, but not JM1 or REH, cells
was increased by the bortezomib treatment (Figure 4D). Signifi-
cantly, in SEM cells, specific knockdown of MLL-AF4 impeded
p27 induction (Figure 4E). Conversely, enforced expression of
MLL-AF4 or MLL-AF9 in REH cells rendered capability to upre-
gulate p27 (Figure 4F). Taken together, these results suggest
that bortezomib principally stabilizes MLL-AF4 or MLL-AF9,
which in turn activates the transcription of the p27 gene
(CDKN1B). Similarly, knockdown of MLL-AF4 in RS4;11 cells
also compromised p27 induction but to a lesser degree, which
could be due to a less efficient knockdown (Figure S4B). Intrigu-
ingly, concurrent knockdown of both MLL-AF4 and MLL by
targeting the shared amino terminus (shMLL-N) in RS4;11 cells
seemed to further impair the p27 induction upon the bortezomib
treatment, implicating a possible assistance of MLL in the MLL-
AF4-dependent induction of p27 (Figure S4B), reminiscent of
what was shown before that MLL-AF9-induced leukemogenesis
required MLL (Thiel et al., 2010).
We further evaluated the mechanisms by which MLL-fusion
proteins contribute to the p27 upregulation. Interestingly,
MLL-fusion partner proteins, including AF4, AF9, ENL, and
ELL, are functional components of the P-TEFb complex (posi-
tive transcription elongation factor b) that functions in transcrip-
tional elongation (Mohan et al., 2010). Moreover, MLL-AF4, but
not MLL, is able to recruit P-TEFb (Yokoyama et al., 2010).
Therefore, we examined whether the bortezomib-stabilized
MLL-AF4 recruits P-TEFb to enhance CDKN1B transcription.
To this end, we performed chromatin immunoprecipitation
(ChIP) assays. In bortezomib-treated REH and SEM cells, anti-
MLL N terminus antibody detected an increased occupancy
of MLL and/or MLL-AF4 at both the CDKN1B promoter and
exon 2 (Figure 4G). Of note, this N terminus antibody recognizes
both MLL and MLL-fusions (Liu et al., 2010). Like the MLL-AF4
protein, cyclin T1, a key component of the P-TEFb complex
(Mohan et al., 2010), was also observed to have an increased
promoter and gene body occupancy in SEM but not REH cells(Figures 4G). Altogether, the body of evidence indicates that
accumulation of MLL-AF4 in response to bortezomib leads to
recruitment of the P-TEFb complex to promote transcriptional
processivity along CDKN1B, thereby increasing the production
of p27 mRNA.
MLL-Fusions Target theCDKN1B Locus throughBinding
B Cell-Specific Transcription Factor PAX5
Recruitment of the P-TEFb complex to the CDKN1B locus by
MLL-AF4 could explain howMLL-fusion proteinsmight stimulate
the induction of p27. However, it could not explain why these
MLL-fusions did not induce p27 in AML cells despite similarly
increased protein abundance. MLL and MLL-fusion proteins
do not consist of any apparent sequence-specific DNA binding
domain (Liu et al., 2009). Therefore, we envisioned that MLL-
fusion proteins may upregulate CDKN1B transcription through
DNA binding protein partners, such as PAX5 and EBF1 (early B
cell factor) transcription factors, that are selectively expressed
in pro-B cells (Busslinger, 2004). By co-immunoprecipitation
assays, MLL-AF4 was found to interact with PAX5, but not
EBF1 (Figures 5A and S5A). OtherMLL-fusion proteins, including
MLL-AF9, MLL-ENL, and MLL-ELL, also interacted with PAX5
(Figure 5B), suggesting that the PAX5-interaction domain of
the MLL-fusion proteins is located within the common MLL
N-terminal 1,400 amino acids. Indeed, whereas the different
MLL translocation partners failed to pull down PAX5 by them-
selves, the amino-terminal 1,400 amino acids of MLL were suffi-
cient to pull down PAX5 (Figure S5B). Mapping experiments
using individual MLL fragments demonstrated that the minimal
interaction domain of MLL encompasses the first 400 amino
acids (Figure 5C).
Using JM1, REH, RS4;11, and SEM pro-B leukemia cells, we
confirmed with co-immunoprecipitation assays that endoge-
nous MLL/MLL-AF4 interacted with PAX5 (Figure 5D). Function-
ally, in SEM cells, knockdown of PAX5 abrogated the ability of
bortezomib to induce p27 mRNA and protein (Figures 5E, 5F,
and S5C). Furthermore, PAX5 knockdown did not affect MLL-
AF4 stability (Figure 5F). We noted that PAX5 levels increased
upon bortezomib treatment (Figure S5D), and this increase
was also associated with an increased PAX5 occupancy at
the CDKN1B promoter (Figure 5G). Moreover, the increased
abundance of MLL/MLL-AF4 at the CDKN1B promoter was
lost when PAX5 was knocked down (Figure 5G), indicating
that PAX5 is required for MLL/MLL-AF4 to bind the CDKN1B
promoter. Our collective data support a model in which
the MLL-AF4 recruitment to the CDKN1B locus depends
on PAX5, and the interaction between MLL-AF4 and PAX5 en-
hances transcriptional processivity of CDKN1B, resulting in
the cell cycle arrest.
Because PAX5 appears to be the critical link for recruiting the
MLL fusion protein to the promoters of cell cycle genes such as
CDKN1B, we assessed the effect of enforced PAX5 expression
in THP-1 cells an acute myelogenous MLL leukemia cell line.
Interestingly, introduction of exogenous PAX5 did not restore
the sensitivity of the MLL-AF9-harboring THP-1 cells to the pro-
teasome inhibitors (Figures S5E and S5F). Furthermore, ChIP
assays revealed that neither ectopically expressed PAX5 nor
MLL or MLL fusion proteins could be recruited to the CDKN1B
promoter (Figure S5G), suggesting that additional factors and/Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc. 535
Figure 4. The p27 Upregulation Plays a Key Role in Bortezomib-Induced Cell Cycle Arrest of Pro-B Leukemia Cells Expressing MLL-Fusions
(A) Cell cycle profiles of the SEM-BCL-XL cells exposed to 5 nM bortezomib for 12 hr were obtained after a 30 min BrdU pulse incorporation, followed by flow
cytometry analyses. Percentages of gated cells are indicated.
(B) Immunoblots of the indicated pro-B leukemic cells following a 12 hr treatment with 5 nM bortezomib.
(C) Top, cell cycle profiles of BCL-2 reconstituted SEM cells expressing shRNA-scramble (shScr) or shRNA-p27 (shp27) were obtained after a 12 hr exposure to
5 nM bortezomib. Bottom left, immunoblots of p27 in knockdown cells. The percentage of the cells in G2/M phase is plotted in the bottom right.
(D) p27 mRNA levels were detected with qRT-PCR in pro-B MLL leukemia cells after a 12 hr treatment with 5 nM bortezomib. Values were normalized against
GAPDH.
(E) The changes of p27 mRNA and protein in the indicated SEM cells upon bortezomib treatment were determined.
(legend continued on next page)
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leukemia cells are likely required for the recruitment of the
PAX5/MLL-fusion complex to it.
Preclinical and Clinical Evidence Supports a Role of
Proteasome Inhibition in Treating Pro-BMLL Leukemias
To investigate if the anticancer effects of proteasome inhibitors
on pro-B MLL-leukemias extend to in vivo settings, we per-
formed xenograft studies by transplanting luciferase-GFP-
tagged REH or SEM cells into NOD-scid Il2rg/ (NSG) recipient
mice. Subsequently, engrafted mice were treated with bortezo-
mib (Luker et al., 2003) and monitored by bioluminescent imag-
ing over approximately 3 weeks. Mice transplanted with REH or
SEM cells without bortezomib therapy developed rapid tumor
progression that was apparent 10 days after transplantation
and that aggressively pervaded nearly the entire animal over
the ensuing 7 days (Figure 6A). Importantly, mice engrafted
with SEM cells and then treated with bortezomib showed a strik-
ing resistance to leukemia accumulation and had only a minor
detectable tumor burden during the same assay period, thus
suggesting significant bortezomib responsiveness in vivo. In
contrast, mice transplanted with REH showed little responsive-
ness to this form of therapy, and displayed a significant tumor
burden (Figure 6A). Hence, similar to the results obtain from
our in vitro studies, our xenograft studies strongly suggested
that bortezomib treatment is an effective agent against pro-B
MLL-AF4 leukemia cells in vivo.
Patients with leukemia bearing MLL translocations generally
have a poor overall prognosis, and this aggressive disease tends
to be refractory to conventional anticancer therapies (Liedtke
and Cleary, 2009). Indeed, MLL leukemia patients frequently suf-
fer relapse after high-dose chemotherapy and/or bone marrow
transplantation. Regrettably, those who fail to respond to stan-
dard therapeutic regimens are often left with limited medical
options. Few clinical trials exist due to the low overall prevalence
of adult MLL-fusion leukemias. A group of five adult MLL leuke-
mia patients, comprised of two pro-B, one biphenotypic, and
two myeloid leukemia cases, were compassionately treated
with bortezomib at standard dosing recommended for multiple
myeloma (Figure 6B and Table S1). Remarkably, patient 1, a
21-year-old female with pro-B MLL-AF4 leukemia, achieved
a complete cytogenetic remission after two standard cycles of
bortezomib (1.3 mg/m2 on days 1, 4, 8, and 11 of a 21 day cycle;
Figure 6C). Due to neurotoxicity, shewas given reduced doses of
bortezomib at 1 mg/m2 once a week as maintenance, which was
discontinued after 8 weeks. This patient remained in complete
remission without further treatment for longer than 1 year. Unfor-
tunately, her leukemia eventually re-emerged and was minimally
responsive to bortezomib, and she died soon thereafter. She
had previously relapsed 6 months after allogeneic bone marrow
transplant from a matched unrelated donor following hyper-
CVAD chemotherapy. Patient 2, who also had pro-B MLL-AF4
leukemia, exhibited nondurable hematologic improvement.(F) The p27 protein level in REH cells expressing either MLL-AF4 or MLL-AF9 aft
(G) ChIP analyses at promoter and exon 2 of the CDKN1B locus on the indicated
antibodies and immunoprecipitates were subjected to quantitative PCR analys
start site.
Error bars reflect ± SEM calculated from three independent experiments. *IndicaPatient 3, who had biphenotypic MLL leukemia, experienced
nondurable reduction in bone marrow blasts. Consistent with
our preclinical findings showing that bortezomib has no efficacy
onmyelogenousMLL leukemia cells, patients 4 and 5 derived no
clinical benefit from bortezomib therapy.
DISCUSSION
Oncogenes, such as MYC, RAS, and E2F1, underlie various
human malignancies and promote cancer formation in various
experimental settings. Yet, despite acting as important drivers
of tumorigenesis, these oncogenes can trigger tumor suppres-
sion in a cell-context and dose-dependent manner (Lowe et al.,
2004). Indeed, whereas moderate oncogene levels induce
cancer initiation and maintenance, high-level expression can
inadvertently activate tumor suppression surveillance programs
including programmed cell death (Murphy et al., 2008; Sarki-
sian et al., 2007). Most notably, excessive Myc overexpression,
in a titratable Myc mouse model, triggers apoptosis through the
induction of BIM and PUMA, ‘‘activator’’ BH3-only molecules
(Egle et al., 2004; Hemann et al., 2004, 2005). Hence, this
mechanism serves as a powerful way to curb the emergence
of cancer and acts as an organismal protective mechanism
(Pelengaris et al., 2002). Similarly, E2F1-induced oncogenesis
is antagonized by apoptosis in RB-deficient cancer cells
(Chen et al., 1999; Mendoza et al., 2003). However, whereas
oncogenes can activate tumor suppression programs, it re-
mains undetermined if such latent programs persist in tumor
cells and whether they can be reactivated and thereby render
clinical benefit for cancer patients. There are obvious important
issues limiting this application. First, in many cancers, driver
oncogenes are overexpressed. Second, during tumor progres-
sion, cancer cells usually acquire additional mutations that
either abolish or bypass inherent tumor suppression functions.
Third, ideal targets should be different between cancer and
surrounding normal cells. Here, we demonstrate that MLL-
fusion proteins can be stabilized and reactivated upon protea-
some inhibition, triggering latent tumor suppression programs
(Figure 7).
The transcriptional regulation of p27 by MLL, MLL-AF9, MLL-
AF4, and MLL-ENL has been reported in various experimental
settings and appears to be very complex (Caslini et al., 2000;
Milne et al., 2005; Wang et al., 2008; Xia et al., 2005). Intriguingly,
in Jurkat cells overexpression of MLL-AF4 induces p27 whereas
in 293T cells it suppresses (Xia et al., 2005). Furthermore, in
human MLL-AF5 leukemia cells KP-L-RY and MLL-ENL-trans-
formed murine myeloid progenitors, pharmacological inhibition
of GSK3 induces p27 and yields preclinical therapeutic benefits
(Wang et al., 2008). In U937 cells, overexpression of the MLL
amino terminus (amino acids 1–410) induces p27 (Caslini et al.,
2000). In pancreatic neuroendocrine cells and transformed
mouse embryonic fibroblasts, wild-type MLL complexes with
Menin to activate p27 (Milne et al., 2005), which further refineser a 12 hr exposure to 5 nM bortezomib.
cells upon bortezomib treatment. Assays were performed with the indicated
es using primers covering the depicted genomic regions. TSS, transcription
tes statistical significance (p < 0.05). See also Figure S4.
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Figure 5. The Recruitment of MLL-AF4 through PAX5 to the CDKN1B Locus Underlies the Specific Cytotoxicity upon Proteasome Inhibition
in Pro-B Leukemia Cells
(A) 293T cells were transfected with FLAG-MLL-AF4 andHA-PAX5 or HA-EBF1 expression constructs as indicated, subjected to anti-FLAG immunoprecipitation,
and analyzed with the indicated antibodies.
(B)293Tcells transfectedwith the indicatedFLAG-MLLconstructs andHA-PAX5weresubjected toanti-FLAG immunoprecipitation, andanalyzedwith immunoblots.
(C) 293T cells transfected with the indicated FLAG-MLL constructs expressing individual MLL amino terminus fragments and HA-PAX5 were subjected to
anti-FLAG immunoprecipitation and analyzed with immunoblots.
(D) An antibody that recognizes the common amino-terminal region of MLL and MLL-fusions was used for immunoprecipitation, and the precipitates were
analyzed with the indicted antibodies.
(E) SEM cells with the indicated knockdown were subjected to qRT-PCR analysis after a 12 hr treatment with 5 nM bortezomib.
(F) PAX5, p27, and MLL-AF4 protein levels of the indicated SEM cells were determined after a 12 hr treatment with 5 nM bortezomib.
(G) SEM cells of the indicated knockdown were subjected to ChIP after a 12 hr treatment with 5 nM bortezomib using the indicated antibodies, and immuno-
precipitates were subjected to quantitative PCR analyses.
Error bars reflect ± SEM calculated from three independent experiments. See also Figure S5.
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Figure 6. The In Vivo Therapeutic Benefits of Proteasome Inhibition in Pro-B MLL Leukemias
(A) NSG mice transplanted with luciferase-expressing REH or SEM cells were treated with bortezomib. On the indicated days after the xenograft, mice were
imaged to assess for leukemia progression. Representative bioluminenscence images are shown on the left and the quantification of bioluminescence (photonic
flux) over the duration of treatment is shown on the right. Error bars reflect ± SEM.
(B) Pathological and clinical summary of five adult patients with MLL leukemia treated with bortezomib.
(C) Hematoxylin and eosin staining of bonemarrow biopsies of patient 1 before (left) and after (right) bortezomib treatment. Scale bars, 100 mm. See also Table S1.
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et al., 2005). Surprisingly, although the loss of Menin in MLL-
ENL-transformed myeloid leukemia blasts results in reduced
Hoxa7 and Hoxa9 expression and thus compromises the leuke-
mia phenotype, the Menin loss under this experimental setting
did not affect Cdkn1b (Yokoyama et al., 2005). Taken together,
most data, including ours, favor a positive correlation between
MLL/MLL-fusion and p27 expression. This begs several
outstanding questions: Why do leukemia fusions activate p27?
Is this a necessity or simply an unwanted byproduct? In favor
of the first scenario, it has been suggested that a low level of
p27 induction by MLL-fusion proteins might prevent leukemia-
initiating cells from exhaustion (Zhang et al., 2013). In favor of
the second scenario, MLL-fusions unavoidably acquire this
context-dependent tumor suppressor activity through the com-mon MLL amino terminus. Nevertheless, this capacity appears
tightly regulated and can be manipulated by pharmacological
means, thereby offering specific therapeutic benefits to patients
with pro-B MLL leukemia.
Collectively, these in vitro results suggest that the latent tumor
suppression activity of MLL-fusion proteins in pro-B MLL leuke-
mia cells can be activated by proteasome inhibitors. In accor-
dance with our in vitro results, proteasome inhibition rendered
therapeutic benefit in an MLL leukemia xenograft mouse model.
Proteasome inhibition also rendered complete remission to one
patient with pro-B MLL-AF4 leukemia that eventually relapsed.
Bortezomib treatment did not appear to benefit the three
patients with AML MLL. Notably, in multiple myeloma, a malig-
nancy for which bortezomib is approved, the rate of response
to bortezomib was 38%.Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc. 539
Figure 7. Illustration Depicts How Proteasome Inhibition Induces
Specific Cytotoxicity in Pro-B MLL Leukemia Cells
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Oncogenic MLL-Fusion-Dependent Tumor SuicideHow pro-B MLL leukemia cells display differential sensitivity
and acquire resistance to proteasome inhibition warrant future
investigation. Because overexpression of BCL-2 or BCL-XL
can abrogate bortezomib-induced apoptosis, apoptosis resis-
tance might represent one refractory mechanism. To overcome
resistance, the potential clinical administration of proteasome
inhibitors in combination with other anticancer agents, such
as cell death-based agents including ABT-263 (Tse et al.,
2008), warrant further investigation. ABT-263, a small molecule
inhibitor of BCL-2, is in clinical trials and has shown effective-
ness and selectivity against certain types of cancers (Davids
and Letai, 2012; Walensky, 2012). In conclusion, our findings
reveal latent tumor suppression programs that can be aroused
through hyperactivating oncogenic fusion proteins. This arousal
might be suitably exploited as a cancer-specific therapeutic
strategy.EXPERIMENTAL PROCEDURES
Reagents
Bortezomib (Velcade) was obtained from Millennium Pharmaceutical. Carfizo-
mib was obtained from Proteolix.Plasmid Constructs
FLAG-tagged fragments consisting of MLL amino acids 1–400, 400–750,
1–750, 750–1,400, 1,400–2,664, and 1–1,400 derived from wild-type MLL
were inserted into eukaryotic expression vectors pCI-neo (Promega) for tran-
sient transfection assays. FLAG-taggedMLL fusion genes, including MLL-AF4
and MLL-AF9, MLL-ENL and MLL-ELL, in eukaryotic expression vector were
described previously (Liu et al., 2007). MLL-AF4 and MLL-AF9 were also
inserted into pMSCV-puro vector (Clontech) for retrovirus production. Full-
length PAX5 and EBF1 were cloned from JM1 cell cDNA and inserted into
the pCMV-HA vector (Clontech). Full-length BCL-2 and BCL-XL were inserted
into the pMSCV-puro (Clontech) or pMIG vector (kindly provided by Dr. William540 Cancer Cell 25, 530–542, April 14, 2014 ª2014 Elsevier Inc.Hahn) for retrovirus production. GFP-tagged CrmA was inserted into pMSCV-
puro vector (Clontech) for retrovirus production.
shRNA-Mediated Knockdown
Target sequence (agaaaagcagacctactcc and ctttaagcagacctactcc) against
human MLL-AF4 in SEM and RS4;11 cells based on published information
(Thomas et al., 2005), target sequence (ttgctccacccatcaaacc) against human
MLL N terminus, target sequence (gaatggacatcctgtataa) against human p27,
and target sequence (ggatgcttgtctatttcta and ggctccccctactattata) against
human PAX5 were inserted into the pSUPER.retro.puro vector, according
to the manufacturer’s protocol (Oligoengine). Generated retrovirus carrying
indicated shRNA was used to infect target cells for 2 days, and the cells
were subjected to puromycin selection at 2 mg/ml.
Immunoblots
The anti-N terminus MLL (MO435) antibodies were generated using a syn-
thetic peptide of MLL amino acids 752–949 as immunogen. Details of the
commercially available antibodies used for immunoblots are available in the
Supplemental Experimental Procedures. Antibodies were detected using
the enhanced chemiluminescence method (Western Lightning, PerkinElmer).
Immunoblot signals were acquired with the LAS-3000 Imaging system
(FujiFilm) and were analyzed with ImageGauge software (FujiFilm) as previ-
ously described (Liu et al., 2010).
Chromatin Immunoprecipitation Assays
ChIP assays were performed using the Magna ChIP A Kit (Millipore) according
to themanufacturer’s protocol. Onemicrogram of pre-immune rabbit IgG, anti-
MLL (MO435), anti-cyclin T1 (Santa Cruz Biotechnology), or PAX5 (Santa Cruz
Biotechnology) antibody was used for each ChIP reaction. Precipitated DNA
was analyzed using a ViiA 7 Real-Time PCR System (Applied Biosystems).
Primers used for ChIP-PCR assay were CDKN1B Promoter (50 base pairs
[bp] to +74 bp relative to TSS): forward, ccaatggatctcctcctctg, reverse, aaaa
caccccgaaaagacg; CDKN1B coding region (+1,441 bp to +1,597 bp relative
to TSS): forward, atttcccctgcgcttagatt, reverse, atcaacccaccgagctgtt.
Mouse Studies and In Vivo Imaging
REH and SEM cells were transduced by lentivirus generated using the FUGW-
FL lentiviral vector that simultaneously expresses GFP and luciferase (Smith
et al., 2004). GFP-positive cells were sorted using MoFlo (Beckman Coulter).
NSG mice were purchased from Jackson Laboratory. One million luciferase-
expressing cells were intravenously injected via the tail vein into NSG mice.
NSG mice were then administered bortezomib intravenously at 0.5 mg/kg on
a twice-weekly schedule beginning 2 days after the xenograft. Total body
bioluminescence was quantified as previously described (Luker et al., 2003).
All animal work was performed in accordance with a protocol approved by
the Animal Studies Committee of Washington University in St. Louis.
Statistics
The Student’s t test was used to analyze the differences between the groups.
A p value less than 0.05 was considered to be statistically significant.
Patients
Retrospective chart review was performed to identify adult patients with MLL
leukemia that was treated with bortezomib at the Barnes Jewish Hospital,
Washington University in St. Louis, between 2007 and 2010. Institutional
Review Board approval for the retrospective data collection was not required.
Patients provided verbal consent for the off-label, off-protocol use of bortezo-
mib for those patientswithMLL leukemia that failed standard of care therapies.
Medical decisions were made at the discretion of the patients’ physicians.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.03.008.
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